In a phase 1/2 study of 115 patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL), 93% achieved complete remission and 87% attained minimal residual disease negativity following CAR-T infusion (NCT03173417) (102). Here, CD19 is linked to acute lymphoblastic leukemia.